‘I recommend starting with a low dose and slowly building up over a few weeks, to find the dose that works best for you,’ agrees Dr Brewer. ‘For example, start with Healthspan High Strength CBD Oil 6.4mg Capsules, taking one to three daily. Then, if needed, move up to Super Strength CBD 15mg Capsules, taking one to two daily. CBD is not psychoactive and is not addictive. I prefer capsules, as CBD drops have a strong taste, although filter-clear peppermint flavoured drops are available.’
In other words, many popular claims remain unfounded – and overlook the fact that there's a difference between CBD that's studied in labs for particular conditions and CBD products that are sold to consumers for general well-being. "What happens is people say, 'Look, CBD is harmless and it doesn't get me intoxicated, so I'm going to take it for what ails me," says Dr. Jordan Tishler, a Harvard physician and CEO of InhaleMD, a Boston-area practice specializing in cannabis therapeutics. "Then they're going to get some perceived benefit because that's the way the placebo effect works, and then they go and trumpet this."
Supercritical CO2 extraction is also the key to understanding more cannabinoids in cannabis like Cannabichromene (CBC) and cannabicitran (CBT) and how they interact with each other (called the Entourage effect). This can lead to increased understanding of marijuana in the medical field, and will also allow growers to come up with more effective, new and exciting strains.
CBD Isolate is the purest supplement available. It’s a 99% pure CBD supplement derived from hemp oil. Despite its concentration, CBD isolate effects are similar to other CBD concentrates, and it can be used in a variety of ways. It can be consumed itself, added to foods and beverages, or vaporized. You can also add it to other CBD products to increase their potency.
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., … & Guimarães, F. S. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Abstract]. Current Pharmaceutical Design, 18(32), 5,131–5,140. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22716160
×